COEPTIS THERAPEUTICS HOLDINGS INC

Company Overview

Coeptis Therapeutics Holdings, Inc. is a small, R&D‑centric holding company in the Healthcare sector and Biotechnology industry that develops cell- and gene‑based immunotherapies and complementary diagnostics through subsidiaries (platforms include GEAR‑NK and SNAP‑CAR). The company is pre‑revenue on its drug programs, has a Class II CD38 in‑vitro diagnostic, and holds licenses and acquired INDs/Phase 1 programs from partners like Deverra and the University of Pittsburgh while co‑developing CD38 assets with Vy‑Gen. Operations are lean (seven employees) and heavily reliant on academic collaborators, CROs and strategic partners for development, manufacturing and commercialization. Management highlights constrained liquidity, recent financing arrangements (a Yorkville SEPA capacity and convertible note facilities), and substantial going‑concern and execution risks typical of early‑stage biotechs.

Executive Compensation Practices

Given the company’s limited cash and pre‑revenue profile, compensation is skewed toward equity and non‑cash awards — management disclosed rising stock‑based compensation and executives waived guaranteed 2023 bonuses to conserve cash. Pay incentives are likely linked to development and partnering milestones (IND filings, in‑vivo/clinical starts, licensing deals and milestone payments), and retention grants are typical to preserve talent in a seven‑person R&D team. As a Biotechnology firm in the Healthcare sector, Coeptis will commonly use option/warrant grants, milestone‑contingent payouts and equity for acquired assets or license considerations (e.g., cash/equity/contingent FHCRC payments). Financial statement volatility from warrant/derivative accounting also means equity awards and warrant liabilities materially affect reported G&A and compensation expense.

Insider Trading Considerations

Limited corporate liquidity and frequent reliance on equity financings increases the likelihood insiders will engage in equity transactions (private placements, participation in SEPA financings or registered sales) — watch Form 4 filings around financing windows. The company’s capital structure includes warrants, convertible notes and derivative liabilities, so insider exercises or conversions can create meaningful dilution and signal confidence when insiders convert or sell following financing closings. Material clinical and licensing milestones (INDs, Phase 1 starts, the Vy‑Gen license, or device regulatory progress) are likely to be market‑moving events that create blackout windows and heightened regulatory risk for trading; investors should monitor 10b5‑1 plans, related‑party financings, and timing of Form 4 filings. Finally, contingent payments and assumed liabilities tied to asset acquisitions create potential conflicts of interest if insiders participate in transactions that affect milestone timing or valuation.